X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Facilities & Operation

Overcoming Emission Challenges For Pharma Sustainability

Content Team by Content Team
29th August 2023
in Facilities & Operation, Featured, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The pharmaceutical industry’s growing emphasis on sustainability reflects the current trends. Although this sector lags behind others in terms of sustainability advancements, there is significant potential to enhance supply chain sustainability in the future.

The global pharmaceutical sector grapples with high energy and water consumption, along with an extensive research and development (R&D) footprint and global factory presence. These factors contribute to substantial pollution, with carbon emissions surpassing those of the automotive industry by 55%, despite the industry being 28% smaller in size. Recognizing the need for change, major pharmaceutical companies such as Johnson & Johnson, MSD, Sanofi, Pfizer, and GSK have committed to renewable energy targets within the next decade.

Although stringent quality control and regulation in the supply chain are essential, the industry lacks clear Environmental, Social, and Governance (ESG) regulations. Current guidelines from regulatory bodies like the Food and Drug Administration (FDA) and the European Medicines Agency do not include environmental standards in their Good Manufacturing Practice (GMP) guidelines. To achieve a more sustainable future, the industry requires well-defined regulatory frameworks and transparent reporting of progress toward sustainability goals.

Despite its high carbon emissions, the pharmaceutical industry faces less external scrutiny compared to industries like oil and gas. There is currently no legislation mandating pharmaceutical companies to report environmental incidents. Achieving sustainability targets necessitates a comprehensive approach throughout the value chain, addressing raw materials for pharmaceutical ingredients, manufacturing processes, and distribution.

Manufacturing pharmaceutical products, while crucial, has a significant carbon footprint. Some companies are adopting continuous manufacturing to reduce their carbon impact. The complex global factory network demands substantial power, prompting the consideration of green power initiatives and solar energy utilization. Additionally, the distribution of medicines from factories to patients incurs environmental costs, especially for temperature-sensitive products. Companies are exploring alternatives to single-use plastics and working on sustainable packaging solutions.

Sustainable packaging is challenging due to strict regulations that ensure medication efficacy and quality. Striking a balance between recyclable and disposable materials is essential. Opportunities for sustainability improvements exist in planning operations, logistics, manufacturing, network design, and packaging. Investment in technology and green power initiatives will be critical for long-term progress. Although the focus on sustainability requires streamlining, positive steps have been taken by leading pharmaceutical players. In the future, the industry will likely face increased scrutiny from government bodies regarding ESG targets, driving collective efforts towards a sustainable future.

Previous Post

Temperature Controlled Pharma Packaging - Onwards & Upwards

Next Post

Pharma Giants Spearhead Eco-Friendly Healthcare Transition

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

Pharma Giants Spearhead Eco-Friendly Healthcare Transition

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In